BGI’s wholly-owned subsidiary won the bid for the whole genome sequencing project of rare disease patients in West China Hospital in Sichuan

Original title: BGI’s wholly-owned subsidiary won the bid for the whole genome sequencing project of rare disease patients in West China Hospital

　　BGI(300676) Evening of June 2announcement, The company’s wholly-owned subsidiary Wuhan Huada Medical Inspection Institute Co., Ltd. (hereinafter referred to as Wuhan Medical Inspection Institute) recently received a “Bid Winning Notice” from the procurement agency Sichuan International Tendering Co., Ltd., and the notice confirms that Wuhan Medical Inspection Institute is ” The winning bidder of the Whole Genome Sequencing Program Procurement Project of 100,000 Cases of Rare Disease Patients in West China Hospital of Sichuan University. The winning bid for this project is RMB 1,348 per case, the number of service cases is expected to be no less than 100,000 cases, and the total amount is no less than 135 million yuan.

The announcement stated that the project is the West China Hospital’s plan to integrate clinical diagnosis and treatment information through whole-genome detection and analysis, and develop a clinical intelligent decision support system for rare and difficult diseases to assist doctors in the diagnosis and treatment of clinically difficult and difficult diseases.

The announcement shows,BGIAs the world‘s leading science and technology service provider and precision medical service operator, we are committed to applying cutting-edge genetic research results and biotechnology to related fields such as people’s livelihood and health, and promoting the industrialization of genetic technology results. The company’s participation in the project’s bid winning and subsequent implementation will help promote the development of genetic technology to support clinical scientific research, help safeguard the health rights of patients with rare diseases, and further enhance and consolidate the company’s leading position in the industry and market.

(Source: China Securities Network)

(Editor in charge: DF537)